全球非阿片类疼痛治疗市场 – 行业趋势及 2029 年预测

市场分析和规模

疼痛管理是医疗的重要组成部分。偏头痛、下背痛、骨关节炎、纤维肌痛、局部肌肉骨骼疼痛和局部神经性疼痛都是慢性疼痛综合征的例子。虽然阿片类药物可能适用于与姑息治疗或临终关怀以及当前癌症治疗相关的急性或慢性疼痛，但也有非阿片类疼痛管理选择。非阿片类疼痛治疗是轻度至中度疼痛的一种选择。非阿片类止痛药无需处方即可获得，也可以作为非处方药。

Data Bridge Market Research 分析，非阿片类疼痛治疗市场在 2021 年为 6.2265 亿美元，到 2029 年将飙升至 8.0732 亿美元，预计在 2022 年至 2029 年的预测期内复合年增长率为 3.30%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

Non-opioid pain relievers are a form of pain reliever that has been specifically created to manage mild to moderate pain. They're commonly used to treat neuropathic pain, cancer pain, orthopaedic and musculoskeletal pain, and other conditions. Medical cannabis, botulinum toxins, capsaicin derivatives, and other non-opioid pain treatments are among the most common.

Non-Opioid Pain Treatment Market Dynamics

Drivers

• Increasing prevalence of osteoarthritis

The rising global prevalence of osteoarthritis, fueled by the ageing population, joint injuries, obesity, repeated stress on the joint, genetics, metabolic illnesses, and bone abnormalities, is expected to fuel demand for non-opioid pain treatment patches. It is the most prevalent type of arthritis, and it most commonly affects the knees, hips, and hands. According to the Osteoarthritis Action Alliance (OAAA), approximately 54.4 million adults in the United States have some type of arthritis, with that number anticipated to rise to 78 million by 2040. Osteoarthritis affects roughly 32.5 million persons in the United States. This tendency is expected to continue in many regions of the world in the future years, propelling the market forward.

• Increasing cases of cancer

Breast, bowel, colorectal, and lung cancer cases are predicted to increase in the next years, propelling the industry forward. The market is expected to benefit from increased awareness among governments in various countries about the availability of novel non-opioid heat patches for the treatment of cancer-related pain. According to the World Health Organization (WHO), cancer will kill approximately 10 million people worldwide in 2020. Breast cancer claimed over 6,85, 000 lives in the same year, while liver cancer claimed 8,30,000 lives and lung cancer claimed 1.80 million lives. This showcases that the prevalence of cancer is set to surge at a fast pace in the near future, which would drive the market.

• High cases of chronic pain-related conditions

The rising prevalence of chronic pain in India is expected to push the non-opioid pain patch market in South Asia. The market is expected to benefit from the government's increasing investments in the construction of a well-established healthcare infrastructure to treat pain-related disorders. Scientists from the All India Institute of Medical Sciences and the Homi Bhabha National Institute, for example, undertook a study in December 2018 to better understand the effect and magnitude of chronic pain across Southeast Asia. A total of 4326 Indian patients were screened, with 836 of them completing a pain questionnaire. Females had a higher incidence (25.2%) than males, and the prevalence increased dramatically among persons aged 65 and up. The numbers are estimated to grow in the near future, thereby augmenting the demand for non-opioid heat patches in India. 

Opportunities

Another important factor expected to boost the market is the growing demand for non-opioid pain management patches due to their ability to reduce the risk of addiction when compared to fentanyl patches when released over a lengthy period of time. In the foreseeable future, the rising demand for minimally invasive therapies is likely to boost growth.

 Restraints/Challenges

However, factors such as high cost of patent drugs and use of opioids in various under developed and developing countries will hinder the non-opioid pain treatment market.

This non-opioid pain treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the non-opioid pain treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Non-Opioid Pain Treatment Market

QMI 团队正在积极监测 COVID-19 对非阿片类止痛药市场的影响。诊所的服务受到全国封锁和全国感染率持续上升的严重影响。由于 COVID-19，许多疼痛和诊所服务的患者就诊量减少，导致客户参与度降低。在 COVID-19 期间，几家诊所和疼痛服务机构的就诊量下降。

近期发展

• 2021 年 1 月，杜克大学领导的科学家团队开发了一种生物相容性手术贴片，可在溶解前数天将非阿片类药物输送到伤口部位。这种新型聚合物贴片可调控释放一种药物，阻断导致炎症和疼痛的酶 COX-2（环氧合酶-2）。
• 2020 年 7 月，美国食品药品监督管理局 (FDA) 批准了一种 8% 辣椒素贴剂，用于治疗糖尿病足部周围神经病变患者的神经性疼痛。该贴剂是一种非阿片类、非全身性和局部性疼痛疗法，被认为是将处方强度辣椒素输送到患者皮肤的唯一方法。

全球非阿片类疼痛治疗市场范围

非阿片类止痛药市场根据产品、治疗应用和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

产品

• 医用大麻
• 含薄荷醇
• 含 Omega 3 脂肪酸
• 肉毒杆菌毒素
• 辣椒素衍生
• 其他的

治疗应用

• 骨科和肌肉骨骼疼痛
• 神经性疼痛
• 癌痛
• 术后疼痛
• 其他的

分销渠道

• 医院 药店
• 零售药店
• 药店
• 邮购药店

非阿片类疼痛治疗市场区域分析/见解

对非阿片类疼痛治疗市场进行了分析，并按国家、产品、治疗应用和分销渠道提供了市场规模洞察和趋势。

非阿片类疼痛治疗市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于临床试验的增多和政府资金的增加，北美在非阿片类疼痛治疗市场占据主导地位。

预计亚太地区将出现显著增长，原因是经济人口结构的变化提高了药品的可负担性，医疗保险的增加以及生产和研发成本的降低提高了印度等新兴国家的制药公司的效率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和非阿片类疼痛治疗市场份额分析

非阿片类止痛药市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对非阿片类止痛药市场的关注有关。

非阿片类疼痛治疗市场的一些主要参与者包括：

• 礼来公司（美国）
• Regeneron Pharmaceuticals Inc.（美国）
• Centrexion Therapeutics Corp.（美国）
• Acorda Therapeutics（美国）
• Biogen（美国）
• VM Biotech（美国）
• 诺华公司（瑞士）
• Alder Biopharmaceuticals（美国）
• 赛诺菲（法国）
• 辉瑞公司（美国）
• 葛兰素史克公司（英国）
• 久光制药株式会社（日本）
• Clarion（美国）
• Endo Pharmaceuticals（爱尔兰）
• 德生制药股份有限公司 (台湾)
• Veridian Healthcare（美国）
• Sorrento Therapeutics, Inc.（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 帝国制药有限公司（日本）

SKU-52491